Hypertension:纵向血压变化与慢性肾脏疾病进展的关系

2021-11-03 从医路漫漫 MedSci原创

在慢性肾脏疾病(CKD)患者中,血压(BP)升高是很常见的,并认为是进展到终末期肾病(ESKD)、心血管疾病和死亡的主要危险因素。

 在慢性肾脏疾病(CKD)患者中,血压(BP)升高是很常见的,并认为是进展到终末期肾病(ESKD)、心血管疾病和死亡的主要危险因素。肾功能逐渐减退时通过交感神经系统过度活跃、肾素-血管紧张素-醛固酮系统和钠潴留导致血压升高。因此,除其他常规措施外,控制血压是糖尿病患者保护肾脏的主要治疗措施,包括减少尿蛋白排泄、限制饮食盐和蛋白质摄入、戒烟、充分控制血糖等。关于BP的纵向时间变化趋势及其对肾功能影响的研究尚不多见。在这里,我们评估了收缩压(SBP)随时间变化的动态变化与不利肾脏预后的关系。

方法:该KNOW-CKD是一项涉及韩国非透析CKD患者的全国性前瞻性队列研究。2011年至2016年,来自9家三级医院的2238名参与者被纳入研究,并随访至2019年3月31日。在2238名参与者中,我们排除了以下患者,因为他们的血压变化无法确定:(1)55名患者只进行了基线检查,此后未进行随访;(2) 95例无基线血压或实验室资料;(3) 105例暴露期间无血压值记录;(4)81例随访时间<1年;(5) 65例患者在基线随访后1年内出现主要预后。最终,1837例患者被纳入分析。为了对BP随时间变化的趋势进行分类,我们应用了基于分组的变化建模。利用这种有限混合建模方法,将纵向BP数据拟合为多个潜在轨迹的混合,并采用时间多项式的截尾正态模型进行拟合。最后,我们确定了3个不同的SBP变化趋势: 268例(14.5%)、1211例(65.9%)和358例(19.5%)患者分别被分为收缩压降低组、收缩压稳定组和收缩压升高组。在0、6和12个月的3次SBP测量中确定。主要结果是CKD进展,定义为估算的肾小球滤过率较基线值或终末期肾病发生的复合结果。

结果:收缩压降低组的收缩压从144mmHg下降到120mmHg,收缩压升高组的收缩压在1年内从114mmHg上升到136mmHg。在6576人年的随访中(中位数,3.7年) ,综合结果发生在521名(28.4%)参与者。收缩压降低组(30.6%)和稳定组(26.5%)的主要预后事件明显少于收缩压升高组(33.0%)。在多变量调整的特定原因危险模型中,与稳定的SBP相比,收缩压增加与不良肾脏结局风险增加1.28倍相关。然而,收缩压下降和稳定组的主要预后风险没有差异。

图1 根据收缩压观察一年内收缩压变化趋势。

表1 根据收缩压变化的结局事件率

图2 根据收缩压变化的肾脏不良结局累积发生率曲线;不良肾脏结局定义为在随访期间估计肾小球滤过率(eGFR)较基线值下降≥50%或终末期肾病发病的复合结果。

表2 根据收缩压变化对综合结局的Cox HR分析

结论:在这项纵向CKD队列研究中,与收缩压稳定相比,收缩压升高组与不良肾脏结局的高风险相关,而收收缩压降低则表现出类似的风险。

原文出处:

 Joo YS,  Kim HW,  Nam KH,et al.Association Between Longitudinal Blood Pressure Trajectory and the Progression of Chronic Kidney Disease: Results From the KNOW-CKD.Hypertension 2021 Aug 15

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1709698, encodeId=50841e096983e, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Wed Dec 29 04:51:19 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729172, encodeId=01661e2917263, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 21:51:19 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039286, encodeId=eb012039286c4, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jul 17 09:51:19 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907775, encodeId=6a8c190e775e3, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Aug 31 12:51:19 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501558, encodeId=aef9150155874, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616227, encodeId=5fbf161622ee4, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066589, encodeId=0e061066589e8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08be1573234, createdName=gyluo2006, createdTime=Wed Nov 03 13:47:49 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066531, encodeId=0a5f10665317d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7ae45643431, createdName=ms5000000151242792, createdTime=Wed Nov 03 10:49:06 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066530, encodeId=7c591066530ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Wed Nov 03 10:46:21 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1709698, encodeId=50841e096983e, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Wed Dec 29 04:51:19 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729172, encodeId=01661e2917263, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 21:51:19 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039286, encodeId=eb012039286c4, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jul 17 09:51:19 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907775, encodeId=6a8c190e775e3, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Aug 31 12:51:19 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501558, encodeId=aef9150155874, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616227, encodeId=5fbf161622ee4, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066589, encodeId=0e061066589e8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08be1573234, createdName=gyluo2006, createdTime=Wed Nov 03 13:47:49 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066531, encodeId=0a5f10665317d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7ae45643431, createdName=ms5000000151242792, createdTime=Wed Nov 03 10:49:06 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066530, encodeId=7c591066530ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Wed Nov 03 10:46:21 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
    2022-09-18 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1709698, encodeId=50841e096983e, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Wed Dec 29 04:51:19 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729172, encodeId=01661e2917263, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 21:51:19 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039286, encodeId=eb012039286c4, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jul 17 09:51:19 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907775, encodeId=6a8c190e775e3, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Aug 31 12:51:19 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501558, encodeId=aef9150155874, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616227, encodeId=5fbf161622ee4, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066589, encodeId=0e061066589e8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08be1573234, createdName=gyluo2006, createdTime=Wed Nov 03 13:47:49 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066531, encodeId=0a5f10665317d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7ae45643431, createdName=ms5000000151242792, createdTime=Wed Nov 03 10:49:06 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066530, encodeId=7c591066530ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Wed Nov 03 10:46:21 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1709698, encodeId=50841e096983e, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Wed Dec 29 04:51:19 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729172, encodeId=01661e2917263, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 21:51:19 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039286, encodeId=eb012039286c4, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jul 17 09:51:19 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907775, encodeId=6a8c190e775e3, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Aug 31 12:51:19 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501558, encodeId=aef9150155874, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616227, encodeId=5fbf161622ee4, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066589, encodeId=0e061066589e8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08be1573234, createdName=gyluo2006, createdTime=Wed Nov 03 13:47:49 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066531, encodeId=0a5f10665317d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7ae45643431, createdName=ms5000000151242792, createdTime=Wed Nov 03 10:49:06 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066530, encodeId=7c591066530ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Wed Nov 03 10:46:21 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1709698, encodeId=50841e096983e, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Wed Dec 29 04:51:19 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729172, encodeId=01661e2917263, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 21:51:19 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039286, encodeId=eb012039286c4, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jul 17 09:51:19 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907775, encodeId=6a8c190e775e3, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Aug 31 12:51:19 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501558, encodeId=aef9150155874, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616227, encodeId=5fbf161622ee4, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066589, encodeId=0e061066589e8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08be1573234, createdName=gyluo2006, createdTime=Wed Nov 03 13:47:49 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066531, encodeId=0a5f10665317d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7ae45643431, createdName=ms5000000151242792, createdTime=Wed Nov 03 10:49:06 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066530, encodeId=7c591066530ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Wed Nov 03 10:46:21 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1709698, encodeId=50841e096983e, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Wed Dec 29 04:51:19 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729172, encodeId=01661e2917263, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 21:51:19 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039286, encodeId=eb012039286c4, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jul 17 09:51:19 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907775, encodeId=6a8c190e775e3, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Aug 31 12:51:19 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501558, encodeId=aef9150155874, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616227, encodeId=5fbf161622ee4, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066589, encodeId=0e061066589e8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08be1573234, createdName=gyluo2006, createdTime=Wed Nov 03 13:47:49 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066531, encodeId=0a5f10665317d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7ae45643431, createdName=ms5000000151242792, createdTime=Wed Nov 03 10:49:06 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066530, encodeId=7c591066530ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Wed Nov 03 10:46:21 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1709698, encodeId=50841e096983e, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Wed Dec 29 04:51:19 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729172, encodeId=01661e2917263, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 21:51:19 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039286, encodeId=eb012039286c4, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jul 17 09:51:19 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907775, encodeId=6a8c190e775e3, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Aug 31 12:51:19 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501558, encodeId=aef9150155874, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616227, encodeId=5fbf161622ee4, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066589, encodeId=0e061066589e8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08be1573234, createdName=gyluo2006, createdTime=Wed Nov 03 13:47:49 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066531, encodeId=0a5f10665317d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7ae45643431, createdName=ms5000000151242792, createdTime=Wed Nov 03 10:49:06 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066530, encodeId=7c591066530ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Wed Nov 03 10:46:21 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
    2021-11-03 gyluo2006

    不错

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1709698, encodeId=50841e096983e, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Wed Dec 29 04:51:19 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729172, encodeId=01661e2917263, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 21:51:19 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039286, encodeId=eb012039286c4, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jul 17 09:51:19 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907775, encodeId=6a8c190e775e3, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Aug 31 12:51:19 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501558, encodeId=aef9150155874, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616227, encodeId=5fbf161622ee4, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066589, encodeId=0e061066589e8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08be1573234, createdName=gyluo2006, createdTime=Wed Nov 03 13:47:49 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066531, encodeId=0a5f10665317d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7ae45643431, createdName=ms5000000151242792, createdTime=Wed Nov 03 10:49:06 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066530, encodeId=7c591066530ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Wed Nov 03 10:46:21 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
    2021-11-03 ms5000000151242792

    谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1709698, encodeId=50841e096983e, content=<a href='/topic/show?id=4cc58893ea0' target=_blank style='color:#2F92EE;'>#血压变化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88937, encryptionId=4cc58893ea0, topicName=血压变化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1b531772449, createdName=ms1467340776200723, createdTime=Wed Dec 29 04:51:19 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729172, encodeId=01661e2917263, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 18 21:51:19 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039286, encodeId=eb012039286c4, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jul 17 09:51:19 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907775, encodeId=6a8c190e775e3, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Wed Aug 31 12:51:19 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501558, encodeId=aef9150155874, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616227, encodeId=5fbf161622ee4, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 04 14:51:19 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066589, encodeId=0e061066589e8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08be1573234, createdName=gyluo2006, createdTime=Wed Nov 03 13:47:49 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066531, encodeId=0a5f10665317d, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7ae45643431, createdName=ms5000000151242792, createdTime=Wed Nov 03 10:49:06 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066530, encodeId=7c591066530ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Wed Nov 03 10:46:21 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
    2021-11-03 1207866fm50(暂无昵称)

    谢谢分享

    0

相关资讯

Lancet:Ziltivekimab可有效降低高动脉粥样硬化风险个体的炎症标志物

采用Ziltivekimab抑制IL-6明显减少了与动脉粥样硬化相关的炎症和血栓形成的生物标志物

Kidney Int:小儿异基因造血干细胞移植后十年内患慢性肾脏疾病的情况

异基因造血干细胞移植(HSCT)被用于治疗血液系统恶性肿瘤、骨髓衰竭综合征、血红蛋白病、先天性免疫缺陷和先天性代谢缺陷的患者。在过去的几十年里,(儿童)HSCT的生存率有了很大的提高,并且已经通过对方

拜耳Finerenone FIDELIO-DKD III期临床研究结果公布

10月27日,拜耳公司公布Finerenone的FIDELIO-DKD研究结果显示:与安慰剂相比,在研药物Finerenone延缓患有慢性肾脏病(CKD)和2型糖尿病(T2D)患者的慢性肾脏病进展。

JAHA:严重主动脉瓣狭窄与慢性肾脏疾病的关系

在严重的主动脉瓣狭窄患者中,中度和重度CKD与死亡率增加和AVR减少有关。无论CKD处于哪一期,AVR均可显著降低全因和心血管死亡率。因此,CKD不应妨碍医师考虑选择AVR。

Nutrients :不吃早餐,晚餐太晚……不健康的饮食习惯可能引起“蛋白尿”

近年来,慢性肾脏疾病(CKD)患者的发病率、住院率均有明显升高,尤其是终末期肾脏疾病,其发病率为每年每百万人287例,而且需要肾脏替代疗法的患者人数还在持续增加。

Am J Clin Nutr:膳食蛋白质摄入量、肾功能和存活率:全国代表性队列研究

人们越来越关注膳食蛋白摄入量(DPI)作为慢性肾脏疾病(CKD)和非CKD人群健康和存活的重要调节因子。在普通人群中,摄入高膳食蛋白质饮食(如原始人饮食、阿特金斯饮食、生酮饮食)已被广泛推广,作为一种